Letter : Human genes: patently not the case
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.From Mr Andrew Sheard
Sir: Your report today on the rejection of the European biotechnology directive by the European Parliament suggests that the biotechnology industry is disappointed with the outcome.
In my experience, both as a Patent Attorney representing various biotechnology companies and as a member of the Industrial Property Advisory Committee of the Bioindustry Association, that is not the case: the industry is in general pleased that the Directive was rejected. What had started out in 1988 as a moderately useful but hardly essential tidying-up exercise in a difficult area of law subsequently became a vehicle for special-interest groups to undermine the growing and established case law which permits the patenting of proteins, DNA and other entities important to the biotechnology industry.
Although industry could have lived with the rather tortured compromise wording eventually put to the European Parliament, frankly there was something of a sigh of relief when the whole package was rejected. The law can now continue its largely harmonised development in a manner that promotes and balances the interests both of the industry and of the consumers who will ultimately benefit from its efforts.
Yours faithfully,
A. G. SHEARD
Kilburn & Strode
Patent Attorneys
London, WC1
2 March
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments